Recovery from diabetes insipidus associated with AML after a BMT conditioning regimen including busulfan

Bone Marrow Transplant. 1993 Feb;11(2):175-6.

Abstract

We describe a patient who, at the onset of acute myelomonocytic leukemia, presented with marked polyuria, polydipsia and laboratory findings consistent with diabetes insipidus (DI). He was treated with vasopressin (DDAVP) with a good response and concurrently induced with daunorubicin and conventional doses of cytosine arabinoside. CR was achieved. The vasopressin requirement decreased progressively, but the patient remained DDAVP-dependent after consolidation treatment. He underwent allogeneic BMT, conditioned with busulfan and cyclophosphamide. By day 15 after BMT vasopressin was no longer required and at a follow-up of 9 months the patient has no evidence of DI. In the absence of specific findings, we think it possible that he had leukemic microinfiltration of the hypothalamic-pituitary area. The drugs used for conditioning may have eradicated CNS disease.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Purging*
  • Bone Marrow Transplantation
  • Busulfan*
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Deamino Arginine Vasopressin / therapeutic use
  • Diabetes Insipidus / drug therapy
  • Diabetes Insipidus / epidemiology
  • Diabetes Insipidus / etiology*
  • Humans
  • Incidence
  • Leukemia, Myelomonocytic, Acute / complications*
  • Leukemia, Myelomonocytic, Acute / drug therapy
  • Leukemia, Myelomonocytic, Acute / surgery
  • Male
  • Remission Induction

Substances

  • Cytarabine
  • Deamino Arginine Vasopressin
  • Busulfan
  • Daunorubicin